Adaptive Biotechnologies projected meaningful growth for its minimal residual disease (MRD) business in 2026, forecasting 20–22% revenue expansion and anticipating ClonoSeq test volume to rise about 30% year‑over‑year. The company said expanded clinical adoption, EMR integrations, and regulatory momentum behind MRD endpoints will drive commercial and clinical trial demand. Adaptive also expects to increase ClonoSeq’s average selling price to roughly $1,400 through payor contract renegotiations and to grow its MRD services for registrational trials. Management framed MRD as a scalable, durable growth engine while affirming the company’s broader immune‑sequencing strategy. MRD refers to highly sensitive assays that detect residual cancer cells after therapy; wider regulatory acceptance of MRD as an endpoint could accelerate lab testing uptake and trial use across hematologic malignancies.